Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 5
2011 6
2012 4
2014 1
2015 5
2016 7
2017 9
2018 11
2019 14
2020 31
2021 55
2022 45
2023 59
2024 63
2025 50
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Cataract Classification Systems: A Review.
Mackenbrock LHB, Labuz G, Baur ID, Yildirim TM, Auffarth GU, Khoramnia R. Mackenbrock LHB, et al. Among authors: khoramnia r. Klin Monbl Augenheilkd. 2024 Jan;241(1):75-83. doi: 10.1055/a-2003-2369. Epub 2024 Jan 19. Klin Monbl Augenheilkd. 2024. PMID: 38242135 Review. English.
Reply.
Friedrich M, Hofmann CA, Chychko L, Son HS, Khoramnia R, Auffarth GU, Augustin VA. Friedrich M, et al. Among authors: khoramnia r. Cornea. 2024 Sep 1;43(9):e20. doi: 10.1097/ICO.0000000000003576. Epub 2024 May 17. Cornea. 2024. PMID: 38759147 No abstract available.
[Ectopia lentis].
Britz L, Auffarth GU, Khoramnia R. Britz L, et al. Among authors: khoramnia r. Ophthalmologie. 2024 Aug;121(8):606. doi: 10.1007/s00347-024-02044-2. Epub 2024 May 3. Ophthalmologie. 2024. PMID: 38700761 German. No abstract available.
[Cerulean cataract].
Britz L, Auffarth GU, Khoramnia R. Britz L, et al. Among authors: khoramnia r. Ophthalmologie. 2024 Jul;121(7):525. doi: 10.1007/s00347-024-02023-7. Epub 2024 Mar 25. Ophthalmologie. 2024. PMID: 38528250 German. No abstract available.
[Liquefied after-cataract].
Fabian K, Kessler LJ, Augustin VA, Auffarth GU, Khoramnia R. Fabian K, et al. Among authors: khoramnia r. Ophthalmologie. 2025 Jan;122(1):1. doi: 10.1007/s00347-024-02077-7. Epub 2024 Jul 4. Ophthalmologie. 2025. PMID: 38965072 German. No abstract available.
Die neuen ANTI-VEGF Präparate: Evolution oder Revolution?
Khoramnia R, Kessler LJ, Auffarth GU, Albrecht M. Khoramnia R, et al. Klin Monbl Augenheilkd. 2025 Mar;242(3):193-195. doi: 10.1055/a-2370-7389. Epub 2025 Feb 5. Klin Monbl Augenheilkd. 2025. PMID: 39909071 German. No abstract available.
326 results